Jaime Brisendine, PA
Physician Assistant · Philadelphia, PANPI 1225086218
Payments from drug & device makers
Across 317 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Lilly USA, LLC$468
- Amgen$382
- AstraZeneca$379
- Teva Pharmaceuticals USA, Inc.$340
- Pfizer$256
- plus $1K from 23 others
What the payments were for
- Speaking & faculty fees$1,85026%
- Food & beverage$5,16974%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 138 | $3,738 |
| Lilly USA, LLC | 22 | $468 |
| Amgen | 27 | $382 |
| AstraZeneca | 18 | $379 |
| Teva Pharmaceuticals USA, Inc. | 20 | $340 |
| Pfizer | 17 | $256 |
| Ipsen Biopharmaceuticals, Inc | 10 | $225 |
| Scilex Pharmaceuticals Inc. | 10 | $200 |
| Lundbeck LLC | 7 | $167 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $151 |
| Impel Pharmaceuticals Inc. | 18 | $145 |
| Novartis | 6 | $123 |
| Boston Scientific | 3 | $63 |
| Upsher-smith Laboratories LLC | 2 | $47 |
| UCB, Inc. | 2 | $39 |
| La Jolla Pharmaceutical Company | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Sanofi | 1 | $24 |
| Impel Pharmaceuticals LLC | 1 | $22 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Almatica Pharma LLC | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Bausch Health US, LLC | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$1,850
How this compares
$7,019 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 33 | $68,037 |
| UbrelvyUbrogepant | 34 | $57,676 |
| Zembrace SymtouchSumatriptan Succinate | 11 | $33,080 |
| QuliptaAtogepant | 25 | $25,833 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 18 | $19,254 |
| Aimovig AutoinjectorErenumab-Aooe | 20 | $14,616 |
| Gabapentin | 54 | $865 |
| Naratriptan Hcl | 29 | $789 |
| RizatriptanRizatriptan Benzoate | 34 | $647 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 28 | $626 |
| Prochlorperazine Maleate | 35 | $607 |
| Tizanidine Hcl | 63 | $565 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 26 | $556 |
| Topiramate | 32 | $526 |
| Amitriptyline Hcl | 12 | $296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $3,738 | $83,50959 claims |
| PfizerNurtec Odt | $256 | $68,03733 claims |
| Upsher-smith Laboratories LLCZembrace Symtouch, Topiramate | $47 | $33,60743 claims |
| Lilly USA, LLCOlanzapine | $468 | $19112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in Philadelphia
- Melissa FerrariPhiladelphia$223K
- Alvin KingcadePhiladelphia$101K
- Trevor BonneyPhiladelphia$44K
- Ashwin GuptaPhiladelphia$33K
- Christopher EsworthyPhiladelphia$31K
- Carolyn ZawislakPhiladelphia$29K
- Kristen JonesPhiladelphia$22K
- Simone HoldenPhiladelphia$17K
- Erin CrownState College$1.5M
- Tricia BootsCranberry Twp$313K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.